Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 6, Issue 12, Pages 1753-1760Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.6.12.1753
Keywords
bevazicumab; CAIX; COX-2; cytokines; renal carcinoma; sorafenib; sunitinib; temsirolimus; VEGF
Categories
Ask authors/readers for more resources
The angiogenic phenotype of renal cell carcinoma results from vascular endothelial growth factor pathway activation. Several different strategies targeting various aspects of the pathway have emerged as clinically relevant therapeutics in metastatic renal cell carcinoma. Key clinical data regarding these approaches are presented in this article. Furthermore, there are several considerations as to the further development of these agents and their appropriate application in metastatic renal cell carcinoma, such as timing of therapy, choice of initial therapy, continued role of debulking nephrectomy and toxicity concerns. These issues are discussed in light of current data and strategies for further drug development are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available